Rokote Laboratories Finland Oy
Startup
Rokote Laboratories Finland Oy is a biotechnology company pioneering intranasal vaccines for infectious diseases. Founded in 2020 as a collaboration between the Universities of Helsinki and Eastern Finland, the company leverages advanced virus vector technologies to develop its FINVac® platform, designed for rapid antigen adaptation, scalable RCA-free production, and easy storage at 4°C or -20°C.
The company’s lead product, FINCoVac® 2.1, is an intranasal COVID-19 vaccine currently in clinical validation. By aiming to induce strong mucosal IgA-driven immunity, it seeks to provide superior infection prevention and reduce transmission, offering clear advantages over injectable mRNA vaccines.
Rokote’s mission is to make vaccines affordable, accessible, and self-administrable, addressing the global need for next-generation immunization. Beyond COVID-19, the FINVac platform can be adapted to other infectious diseases, creating opportunities for out-licensing, co-development, and partnerships with pharmaceutical companies and global health organizations.
Led by internationally recognized experts in virology and gene therapy, Rokote is positioned to become a leading innovator in intranasal vaccine technology, with significant global market potential.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events